TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?

被引：49
作者：
De Meulenaere A. [1 ]
Vermassen T. [1 ]
Aspeslagh S. [2 ]
Vandecasteele K. [3 ]
Rottey S. [1 ]
Ferdinande L. [4 ]
机构：
[1] Department of Medical Oncology, Ghent University Hospital, De Pintelaan 185, Ghent
[2] DITEP, Gustave Roussy Cancer Centre, rue Edouard-Vaillant 114, Villejuif
[3] Department of Radiation Oncology, Ghent University Hospital, De Pintelaan 185, Ghent
[4] Department of Pathology, Ghent University Hospital, De Pintelaan 185, Ghent
来源：
Head and Neck Pathology | 2017年 / 11卷 / 3期
关键词：
Biomarker; Prognosis; Squamous cell carcinoma of the head and neck; Tumor infiltrating lymphocytes;
D O I：
10.1007/s12105-016-0776-8
中图分类号：
学科分类号：
摘要：
The assessment of tumor infiltrating lymphocytes (TILs) has recently emerged as a prognostic biomarker in several solid tumors. Quantification and subtyping of TILs reflects the immune response in the tumor microenvironment, contributing to either tumoral immune attack or escape and thereby affecting outcome. Despite the growing evidence of its value as prognosticator, TILs analysis has not yet found its way to daily clinical practice. The aim of this review is to evaluate whether the current knowledge on TILs in head and neck cancer justifies its clinical implementation. Therefore, we summarize the data on TILs in squamous cell cancer of the head and neck with focus on the most important subsets (T lymphocytes and more specifically CD8+ cytotoxic T cells and FoxP3+ regulatory T cells) and site-specific characteristics such as Human Papilloma Virus infection. In addition, we discuss methodological problems and pitfalls that can account for discordant findings and that may hamper inclusion of TILs assessment in routine practice of pathologists and oncologists. © 2017, Springer Science+Business Media New York.
引用
收藏
页码：354 / 363
页数：9
相关论文
共 65 条
  • [1] Ferlay J., Shin H., Bray F., Forman D., Mathers C., Maxwell Parkin D., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 27, 12, pp. 2893-2917, (2010)
  • [2] Wyss A., Hashibe M., Chuang S.C., Lee Y.C., Zhang Z.F., Yu G.P., Et al., Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium, Am J Epidemiol, 178, 5, pp. 679-690, (2013)
  • [3] Hashibe M., Brennan P., Benhamou S., Castellsague X., Chen C., Curado M.P., Et al., Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium, J Natl Cancer Inst, 99, 10, pp. 777-789, (2007)
  • [4] Chaturvedi A.K., Engels E.A., Pfeiffer R.M., Hernandez B.Y., Xiao W., Kim E., Et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States, Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 29, 32, pp. 4294-4301, (2011)
  • [5] Ramqvist T., Dalianis T., Oropharyngeal cancer epidemic and human papillomavirus, Emerg Infect Dis, 16, 11, pp. 1671-1677, (2010)
  • [6] Nasman A., Attner P., Hammarstedt L., Du J., Eriksson M., Giraud G., Et al., Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?, International journal of cancer Journal international du cancer, 125, 2, pp. 362-366, (2009)
  • [7] Attner P., Du J., Nasman A., Hammarstedt L., Ramqvist T., Lindholm J., Et al., The role of human papillomavirus in the increased incidence of base of tongue cancer, International journal of cancer Journal international du cancer, 126, 12, pp. 2879-2884, (2010)
  • [8] Gregoire V., Lefebvre J.L., Licitra L., Felip E., Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 21, pp. v184-v186, (2010)
  • [9] Schreiber R.D., Old L.J., Smyth M.J., Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion, Science, 331, 6024, pp. 1565-1570, (2011)
  • [10] Mittal D., Gubin M.M., Schreiber R.D., Smyth M.J., New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape, Curr Opin Immunol, 27, pp. 16-25, (2014)
1234567